Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bone marrow mononuclear cells (BMMNC) are a heterogeneous population of cells derived from bone marrow that include mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs), and hematopoietic stem cells (HSCs). In the context of therapeutic applications, such as post-prostatectomy erectile dysfunction, these cells are typically harvested autologously and injected locally. The mechanism of action involves the potential replacement of damaged penile cells (endothelial, smooth muscle, and mesenchymal cells) and the secretion of paracrine factors that promote angiogenesis, reduce apoptosis, and mitigate fibrosis in the corpus cavernosum. This regenerative approach aims to restore natural erectile function by addressing the underlying vascular and cellular damage caused by radical prostatectomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bone marrow mononuclear cells (Inserm).